SCHEMBL1402853

SCHEMBL1402853

Cc1ccc(S(=O)(=O)Nc2cccc(C=CC(=O)Cl)c2)cc1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC4 P56524 7/20 0.76
HDAC1 Q13547 7/20 0.76
HDAC8 Q9BY41 6/20 0.76
HDAC3 O15379 5/20 0.76
HDAC7 Q8WUI4 5/20 0.76
HDAC2 Q92769 5/20 0.76
HDAC10 Q969S8 5/20 0.76
HDAC11 Q96DB2 5/20 0.76
HDAC6 Q9UBN7 5/20 0.76
HDAC9 Q9UKV0 5/20 0.76
HDAC5 Q9UQL6 5/20 0.76
THRB P10828 1/20 0.61
HTT P42858 1/20 0.61
LMNA P02545 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
NPSR1 Q6W5P4 1/20 0.57
TCF4 P15884 1/20 0.55
CTNNB1 P35222 1/20 0.55
SPHK2 Q9NRA0 1/20 0.54
SPHK1 Q9NYA1 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1402851 1.00 HDAC4 (0.76) HDAC4HDAC1HDAC8HDAC3HDAC7
SCHEMBL1403046 0.89 HDAC4 (0.78) HDAC4HDAC1HDAC8HDAC3HDAC7
SCHEMBL1403048 0.89 HDAC4 (0.78) HDAC4HDAC1HDAC8HDAC3HDAC7
SCHEMBL1403261 0.88 HDAC3 (0.74) HDAC4HDAC1HDAC8HDAC3HDAC7
SCHEMBL1403264 0.88 HDAC3 (0.74) HDAC4HDAC1HDAC8HDAC3HDAC7
SCHEMBL1403632 0.88 HDAC1 (0.76) HDAC4HDAC1HDAC8HDAC3HDAC7
SCHEMBL1403634 0.88 HDAC1 (0.62) HDAC4HDAC1HDAC8HDAC3HDAC7
SCHEMBL1403633 0.88 HDAC1 (0.76) HDAC4HDAC1HDAC8HDAC3HDAC7
SCHEMBL1413382 0.86 HDAC1 (1.00) HDAC4HDAC1HDAC8HDAC3HDAC7
SCHEMBL1413385 0.86 HDAC1 (1.00) HDAC4HDAC1HDAC8HDAC3HDAC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2292593-A2 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors TopoTarget UK Limited (GB) 2011-03-09 EP disclosed
US-7557140-B2 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors TOPOTARGET UK LIMITED (GB) 2009-07-07 US disclosed
US-7407988-B2 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors TOPOTARGET UK LIMITED (GB) 2008-08-05 US disclosed
US-20080161401-A1 CARBAMIC ACID COMPOUNDS COMPRISING A SULFONAMIDE LINKAGE AS HDAC INHIBITORS TOPOTARGET UK LIMITED (GB) 2008-07-03 US disclosed
US-7183298-B2 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors TOPOTARGET UK LIMITED (GB) 2007-02-27 US disclosed
US-20070004806-A1 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors TOPOTARGET UK LIMITED (GB) 2007-01-04 US disclosed
US-20050107445-A1 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors PROLIFIX LIMITED (GB) 2005-05-19 US disclosed
US-6888027-B2 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors TOPOTARGET UK LIMITED (GB) 2005-05-03 US disclosed
US-20050085515-A1 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors TOPO TARGET UK LIMITED, (GB) 2005-04-21 US disclosed
US-20040077726-A1 Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors SWK FUNDING LLC 2004-04-22 US disclosed
EP-1328510-A2 CARBAMIC ACID COMPOUNDS COMPRISING A SULFONAMIDE LINKAGE AS HDAC INHIBITORS PROLIFIX LTD. (GB) 2003-07-23 EP disclosed
WO-2002030879-A2 CARBAMIC ACID COMPOUNDS COMPRISING A SULFONAMIDE LINKAGE AS HDAC INHIBITORS PROLIFIX LIMITED (GB) 2002-04-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107445-A1 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors HDAC1, HDAC11, HDAC3 HDAC4 8/4885HDAC1 1/4885HDAC8 4/4885
US-20070004806-A1 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors HDAC1, HDAC11, HDAC3 HDAC4 8/4885HDAC1 1/4885HDAC8 4/4885
US-20080161401-A1 CARBAMIC ACID COMPOUNDS COMPRISING A SULFONAMIDE LINKAGE AS HDAC INHIBITORS HDAC1, HDAC11, HDAC3 HDAC4 8/4885HDAC1 1/4885HDAC8 4/4885
US-20040077726-A1 Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors HDAC1, HDAC11, HDAC2 HDAC4 8/4885HDAC1 1/4885HDAC8 4/4885
US-20050085515-A1 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors HDAC1, HDAC11, HDAC3 HDAC4 8/4885HDAC1 1/4885HDAC8 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.